LEXXW - Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
(TheNewswire)
“Cannabinoids have the potential to prevent aswell as treat infection by SARS-CoV-2 ”
Kelowna, British Columbia – TheNewswire - January 18, 202 2 – LexariaBioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms,comments on an independent January 10 study, availablehere , that discovered that“Cannabinoids Block Cellular Entry of SARS-CoV-2 and the EmergingVariants”.
In an interview granted to vice.com, lead researchscientist Dr. Richard van Breemancommented on how smoking or vaping ofcannabis was likely not effective, while oral delivery was effective.“ I f these hemp products containing thesecompounds are smoked or vaped, the heat exposure could cause thechemical decomposition or conversion… So, we would recommend infavor of an oral administration of these compounds instead of smokingthem, inhaling them from vaping.”
“Lexaria has led the conversation for years relatedto oral delivery of cannabinoids and is a world-leader through itspioneering drug delivery technology, DehydraTECH TM , in moreeffective delivery of cannabinoids to the human bloodstream throughoral means,” said Chris Bunka, CEO of LexariaBioscience.
In the peer-reviewed study, the researchers concludedthat “Cannabinoid acids from hemp ( Cannabis sativa )were found to be allosteric as well as orthosteric ligands withmicromolar affinity for the spike protein. In follow-up virusneutralization assays, cannabigerolic acid and cannabidiolic acidprevented infection of human epithelial cells by a pseudovirusexpressing the SARS-CoV-2 spike protein and preventedentry of live SARS-CoV-2 alpha variant B.1.1.7 and the beta variantB.1.351.”
Lexaria is actively engaged in research withDehydraTECH-powered cannabinoid formulations across a range ofpotential therapeutic applications, including an advanced oralDehydraTECH-CBD formulation that it is preparing for registeredclinical trials as a prospective new pharmaceutical product. Moreover,the patented DehydraTECH process does not involve processingtemperatures remotely as high as those encountered in smoking orvaping processes, and in previous studies has been found to leave thecannabinoid molecules undamaged.
In other work previously conducted by Lexaria andannounced on June 3, 2021, we discovered that Lexaria’sDehydraTECH-enabled remdesivir and ebastine effectively inhibit theCOVID-19 SARS-CoV-2 Virus. Remdesivir is awell-known nucleotide reverse transcriptase inhibitor, available underthe trade name Veklury® from Gilead Sciences Inc., that interfereswith the SARS-CoV-2 viral replication life cycle and has receivedemergency use authorization in many regions of the world for treatment ofCOVID-19 . Ebastine is anantihistamine drug that has potent effects in inhibiting theSARS-CoV-2 main protease (Mpro, also called the 3CL protease) blockingviral entry into humancells , together with effects to reduce COVID-19inflammatory reactions . Mproinhibitors are gaining attention in the fight against COVID-19, asannounced by Pfizer with their novel compoundPF-07304814 .
The Company is not making any express or implied claimsthat it has the ability to eliminate, cure or contain COVID-19 (or theSARS-CoV-2) virus.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting more effectiveoral delivery. Since 2016, DehydraTECH has repeatedly demonstrated theability to increase bio-absorption withcannabinoids and nicotine by 5-10x and, in someinstances with cannabinoids by as much as 27x compared to standardindustry formulations, reduce time of onset from 1 - 2 hours tominutes, and mask unwanted tastes; and is also being evaluated fororally administered anti-viral drugs, non-steroidal anti-inflammatorydrugs (NSAIDs), PDE5 inhibitors and more. DehydraTECH has alsoevidenced an ability to deliver some drugs more effectively across theblood brain barrier. Lexaria operates a licensed in-house researchlaboratory and holds a robust intellectual property portfolio with 23patents granted and over 50 patents pending worldwide. For moreinformation, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances or otherwise, exceptas otherwise required by law.
George Jurcic - Headof Investor Relations
Copyright (c) 2022 TheNewswire - All rights reserved.